Aw Katherine, Gavigan Genevieve
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Division of Dermatology, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
SAGE Open Med Case Rep. 2025 Jan 2;13:2050313X241304891. doi: 10.1177/2050313X241304891. eCollection 2025.
Discoid lupus erythematosus is a chronic, recurring, autoimmune skin disease causing annular, scarring plaques on the head and neck. Deucravacitinib, a tyrosine kinase 2 inhibitor in the Janus kinase inhibitor family, represents an emerging treatment option in systemic lupus erythematosus with potential applicability to discoid lupus erythematosus. We describe a 48-year-old woman with multiple treatment-refractory scalp plaques and associated alopecia treated with deucravacitinib. She demonstrated resolution of symptoms and 1-2 cm hair regrowth at a 3-month follow-up, with significant hair regrowth and reduction in plaque size at a 6-month follow-up. The patient tolerated the medication well with no side effects. This case highlights the potential of deucravacitinib as an effective therapy for refractory discoid lupus erythematosus.
盘状红斑狼疮是一种慢性复发性自身免疫性皮肤病，可在头颈部引起环形瘢痕性斑块。度普利尤单抗是一种Janus激酶抑制剂家族中的酪氨酸激酶2抑制剂，是系统性红斑狼疮的一种新兴治疗选择，可能适用于盘状红斑狼疮。我们描述了一名48岁女性，有多个对治疗耐药的头皮斑块并伴有脱发，接受了度普利尤单抗治疗。在3个月的随访中，她的症状得到缓解，头发再生了1 - 2厘米，在6个月的随访中，头发显著再生，斑块大小减小。患者对该药物耐受性良好，无副作用。该病例突出了度普利尤单抗作为难治性盘状红斑狼疮有效治疗方法的潜力。
